This is a study of treatment for body dysmorphic disorder (BDD) in adolescents. People with BDD worry about their appearance, which causes them distress or interference with their functioning. This study is evaluating the effectiveness of the medication fluoxetine (Prozac) vs placebo (sugar pill) in BDD. This is a 12 week study for adolescents, ages 12 to 18. All study participants will receive fluoxetine treatment during the study. Participants are paid for their participation.

Condition	Treatment or Intervention
Body Dysmorphic Disorder	Drug: fluoxetine

Further Study Details: 

Expected Total Enrollment:  100

Ages Eligible for Study:  12 Years   -   18 Years,  Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA: (partial listing)

• A diagnosis of DSM-IV BDD variant must be present currently and for at least 6 months prior to study entry

EXCLUSION CRITERIA: (partial listing)

• Schizophrenia or schizoaffective disorder
• Current or lifetime DSM-IV bipolar disorder
• History of seizure disorder

New York
      Mount Sinai Hospital, New York,  New York,  10029-6574,  United States
Ohio
      University of Cincinnati, Cincinnati,  Ohio,  45267,  United States
Rhode Island
      Butler Hospital, Brown University School of Medicine, Providence,  Rhode Island,  02906,  United States

Study ID Numbers:  58750
Record last reviewed:  January 2005
Last Updated:  January 7, 2005
Record first received:  January 11, 2002
ClinicalTrials.gov Identifier:  NCT00029471
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08